Refine by
Autoimmune And Infectious Diseases Articles & Analysis: Older
108 news found
Therefore, flow cytometry is widely used in clinical diagnosis and medical research, such as tumor-associated diseases, autoimmune diseases, cardiovascular diseases, inflammatory infections and infectious diseases, providing higher clinical value for differential diagnosis, treatment monitoring ...
Insights into this paradigm are expected to link the regulation of pathways to the restoration of immune homeostasis for the treatment of a wide range of diseases, including infectious diseases, autoimmune disorders, allograft rejection and malignancies. ...
This critical information holds immense potential in unraveling immune responses, gaining insights into autoimmune diseases, advancing cancer immunotherapy, and propelling vaccine development. ...
Antibody-based therapies have witnessed unprecedented success in treating a wide array of diseases, from cancer to autoimmune disorders. However, the traditional antibody discovery process is labor-intensive, time-consuming, and costly. ...
With expertise in antibody generation and immunoassay development, Creative Diagnostics can generate various diagnostic antibodies covering a wide range of diseases, including infectious diseases, cardiovascular diseases, cancer and bone diseases, especially osteoporosis. In addition, Creative Diagnostics ...
HLA regions are associated with the greatest number of human diseases in the human genome, and HLA typing is particularly important for assessing immune compatibility between organ donor and recipient pairs. There are more than 100 kinds of diseases related to HLA, involving autoimmune diseases, immunodeficiency ...
Biolojic uses its proprietary AI platform to design antibodies with new capabilities to cure disease, ushering in a new era of smart therapeutics Biolojic Tel Aviv to focus on computational design of antibodies; Boston location will focus on drug development Biolojic Design, a unique technology company pioneering computational design of human antibodies to develop smart therapeutic ...
Dr. Ali Tinazli's post at the Forbes magazine about "History Of Health Technologies And Meaningful Change In The Era Of Health 4.0" The medicine in ancient Egypt is some of the oldest in history. Although rudimentary, it was already highly personalized and with exclusive access. During the Renaissance—one of the most remarkable ages of humankind—medicine ...
Gene expression and therapy involves the introduction of foreign nucleic acids into target cells to modify or compensate for gene defects, thereby treating diseases such as cancer, diabetes, autoimmune diseases, and infectious diseases. ...
Creative BioMart, a biotechnology company that offers a wide range of solutions dedicated to helping researchers and pharmaceutical companies discover and develop novel drugs in the treatment of cancer, autoimmune diseases, etc., now offers MHC solutions for cell therapy and vaccine development. According to the official speaker from Creative BioMart, based on MHC-like complexes that can ...
Jubilant Therapeutics Inc., a clinical stage biopharmaceutical company developing precision oral medicines with enhanced therapeutic index to serve genetically defined patients suffering from cancer and autoimmune diseases, today announced that Syed Kazmi, Chief Executive Officer, will be making a business update presentation and meeting with institutional investors at the following conferences ...
BioPharma: Microbiome therapeutics, anti-microbial resistance, personalised/stratified medicine, therapeutics for gastrointestinal and infectious diseases, immuno-oncology/autoimmune disease and metabolic health. ...
Results of an analysis of a previous prevention trial with Diamyd® (GAD-alum) treatment, which indicate a positive and sustained immunomodulating effect after treatment with Diamyd® in healthy children at risk for type 1 diabetes, have been published in the scientific journal Journal of Immunology Research. The analysis was carried out by researchers at Lund University and provides ...
BRYAN, Texas and SAN DIEGO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System, today announces preliminary unaudited financial results for the fiscal year ended June 30, 2022, and provides a corporate update. “We ...
iBio is jockeying for position as a leading player in Al-powered drug discovery while also expanding its immuno-oncology pipeline after closing on the acquisition of multiple assets from its partner, RubrYc Therapeutics. The plant-based drug developer and contract development and manufacturing organization (CDMO) said the deal shores up its ambition to bring immunotherapies to the clinic, ...
Unlike other traditional and newer AI-driven methods of drug discovery that often focus upon dominant epitopes, the RubrYc Discovery Engine uses predictive algorithms to identify and model subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Previously Licensed Candidates: All ...
Updated 12-month results from the open-label investigator-initated Phase II clinical trial GADinLADA that assessed three intralymphatic injections of the therapeutic diabetes vaccine Diamyd® in individuals diagnosed with Latent Autoimmune Diabetes in Adults (LADA) were presented today at the European Association for the Study of Diabetes (EASD) conference in Stockholm, Sweden. The updated ...
Researchers in the laboratory of Yulia Nefedova, M.D., Ph.D., at The Wistar Institute and collaborators at the Jubilant Therapeutics Inc. have uncovered a novel mechanism by which protein arginine deiminase 4 (PAD4) in neutrophils promotes cancer progression. The paper also found that inhibition of this function of PAD4 reduces primary tumor growth and metastasis and enhances checkpoint inhibitor ...
Shanghai, China and Rapperswil, Switzerland) Shanghai Fosun Pharma (Group) Co. (“Fosun Pharma”, stock code : 600196.SH; 02196.HK) announced that Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. (“Fosun Pharmaceutical Industry”), a controlled subsidiary, signed an exclusive sales agency and development agreement with Switzerland ’s Neovii Pharmaceuticals ...
Who can benefit from an adjustable gastric band implant? Adults between the ages of 18 and 60 years with morbid obesity (BMI of > 40) or severe obesity (BMI of > 35) with at least one complication (diabetes, hypertension, sleep apnea syndrome, joint disorders) People who have already tried to lose weight without success despite receiving specialized medical care for several months ...